Previous 10 | Next 10 |
Shares of Travere Therapeutics Inc. (NASDAQ:TVTX) traded at a new 52-week low today of $13.10. So far today approximately 130,000 shares have been exchanged, as compared to an average 30-day volume of 898,000 shares. Travere Therapeutics Inc is a biopharmaceutical company. The company is...
Travere suffered two major setbacks recently. The stock is trading at 52-week lows as a result. This presents a cautious opportunity. For further details see: Travere: Setback Presents Cautious Opportunity
Travere Therapeutics Inc. (NASDAQ:TVTX) traded today at a new 52-week low of $13.80. So far today approximately 130,000 shares have been exchanged, as compared to an average 30-day volume of 1 million shares. Based on a current price of $13.96, Travere Therapeutics Inc. is currently 16.6...
Travere Therapeutics Inc. (NASDAQ:TVTX) traded at a new 52-week low today of $13.40. Approximately 130,000 shares have changed hands today, as compared to an average 30-day volume of 1 million shares. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the ...
SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 89,950 shares of its common stock to eleven new employ...
After disappointing news from the FDA, Travere Therapeutics Inc. (TVTX) declined for a while, but has since fallen into a sideways trading range, where it has formed a resistance level of resistance and a level of support. If the stock breaks through either level, a big move is expected. Read...
The following slide deck was published by Travere Therapeutics, Inc. in conjunction with this event. For further details see: Travere Therapeutics (TVTX) Investor Presentation - Slideshow
Shares of Travere Therapeutics Inc. (NASDAQ:TVTX) traded today at $13.98, breaking its 52-week low. Approximately 130,000 shares have changed hands today, as compared to an average 30-day volume of 738,000 shares. Travere Therapeutics Inc is a biopharmaceutical company. The company is fo...
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin II type 1 (AT1) receptor...
Travere Therapeutics Inc. (NASDAQ:TVTX) traded at a new 52-week low today of $14.08. This new low was reached on below average trading volume as 130,000 shares traded hands, while the average 30-day volume is approximately 738,000 shares. Based on a current price of $14.15, Travere Thera...
News, Short Squeeze, Breakout and More Instantly...
Travere Therapeutics Inc Com Company Name:
TVTX Stock Symbol:
NASDAQ Market:
2024-05-04 22:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss...
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) ...